Siemens Forms Molecular Imaging Unit

(Culver City, CA, USA), a leading developer of positron emission tomography (PET) imaging equipment and services.

CTI is a wholly owned subsidiary of Siemens Medical Solutions, acquired by Siemens in May 2005 in a transaction valued at around U.S.$1 billion. With this acquisition and the formation of a division centered on PET and single photon emission computed tomography (SPECT)-based molecular imaging technologies, Siemens strengthens its dedication to molecular imaging development, technologic innovation, and the creation of dynamic new technologies that will update the diagnosis and treatment of disease. This includes the development and distribution of molecular biomarkers, preclinical imaging for research and pharmaceuticals, and application and post-processing for molecular imaging.

"Uniting Siemens Nuclear Medicine with CTI to form a new molecular
imaging division supports our vision to be the innovation trendsetter
in the healthcare industry,” said Erich Reinhardt, Ph.D., president and CEO, Siemens Medical Solutions.

"CTI and Siemens are two pioneering companies in the healthcare technology field,” said Ronald Nutt, Ph.D., founder and former president and CEO of CTI Molecular Imaging, who is now the chief scientific advisor of the new Siemens division. "This new partnership marks an exciting step in our quest to discover and pursue new paths in molecular medicine, and reflects our overall strategy to personalize healthcare and positively impact the way illness is identified and treated.”





Related Links:
Siemens Medical Solutions
CTI Molecular Imaging